Skip to main content

Multi-track investment for CordenPharma

CDMO CordenPharma is planning to invest heavily in all its platforms in terms of both capacities and capabilities, according to Dr Stephen Houldsworth, global head of platform management and marketing, who spoke with SCM at CPhI Worldwide in Milan.

In high potency, Houldsworth said, the firm has just signed off on an expansion of its development capabilities at Plankstadt in Germany. It is also expanding high potency capsule manufacture, where before Plankstadt was mostly focused on tablets, while adding hot melt extrusion to address bioavailability challenges.

Minafin reorganises itself

As “part of its strategy to meet the evolution of customer needs in fine chemicals and services”, the Minafin Group has reorganised itself into three divisions, each with its own CEO, with effect from 1 October. They are:

* Health Chemistry, comprising the pharmaceutical activities of Minakem CDMO, Minakem Generics and HPAPIs, led by a CEO who is as yet unannounced

* Green Chemistry, comprising the mainly non-pharma activities of Pennakem, Minasolve, Minagro and EcoXtract, under Gust Desmedt

Delaware for WuXi STA campus

Chinese CDMO WuXi STA is to build a new pharmaceutical clinical and commercial manufacturing complex on a 78-hectare campus in Middletown, Delaware. This has been supported by the Delaware Prosperity Partnership, other state departments and local government bodies, and received grants from the Delaware Strategic Fund.

KD Pharma buys RohnerChem site

German CDMO KD Pharma, which is one of the world’s largest producers of omega-3 fatty acids has acquired the assets of former CDMO RohnerChem at Pratteln, near Basel, Switzerland (pictured), and hired some of the former team. Terms were not disclosed.

KD said that it aims to become an even bigger player and that the site’s “unique chemical processes and technological capabilities” enabled it “to manufacture difficult, multi-step pharmaceutical intermediates and APIs. This is a natural fit with our strategy.”

Grace buys Albemarle FCS

W.R. Grace & Co. has agreed to acquire the Fine Chemistry Services (FCS) business of its fellow US speciality chemicals company, Albemarle, in a deal that is expected to close in Q2, subject to regulatory approvals and other customary conditions. This will bring Grace sites at Tyrone, Pennsylvania, and South Haven, Michigan. FCS will fit within Pharma & Consumer, which Grace described as “the largest, fastest growing and most profitable sub-segment” in its Materials Technologies business.

New owner for Arcinova

UK-based CDMO Arcinova has been acquired by Quotient Sciences, a ‘drug development and manufacturing accelerator’ that is itself owned by private equity firm Permira. BGF, which had part-owned Arcinova since 2018, will withdraw from its minority stake. Terms were not disclosed.

Carbogen Amcis plans two projects

Swiss-based CDMO Carbogen Amcis has announced two major expansion projects over the next four years at a cost of over €90 million. This follows six years of constant growth for the company, a subsidiary of the Dishman Group, and aims to address current market demand.

Subscribe to CDMO